<?xml version="1.0" encoding="UTF-8"?>
<p id="par0255">The FDA has recently approved convalescent plasma for serious or immediately life-threatening COVID-19 infections under emergency Investigational New Drug Application (eINDs) [
 <xref rid="bib0400" ref-type="bibr">80</xref>]. Convalescent plasma has been previously studied during other epidemics including H1N1 influenza virus pandemic, SARS-CoV-1 epidemic, and the MERS-CoV epidemic. Recently, a preliminary case series of five intubated COVID-19 patients with ARDS showed promising results. These patients received 400 ml of convalescent plasma containing neutralizing SARS-CoV-2–specific antibody (IgG) from recovered COVID-19 donors. All patients had gradual clinical and radiological improvement within 3 days and four patients no longer required respiratory support by day 9, viral loads also became negative within 12 days after transfusion. Seven clinical trials are currently registered [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0190" ref-type="bibr">38</xref>,
 <xref rid="bib0405" ref-type="bibr">81</xref>].
</p>
